Skip to Content
Merck
CN
  • Type II alveolar cell MHCII improves respiratory viral disease outcomes while exhibiting limited antigen presentation.

Type II alveolar cell MHCII improves respiratory viral disease outcomes while exhibiting limited antigen presentation.

Nature communications (2021-06-30)
Sushila A Toulmin, Chaitali Bhadiadra, Andrew J Paris, Jeffrey H Lin, Jeremy Katzen, Maria C Basil, Edward E Morrisey, G Scott Worthen, Laurence C Eisenlohr
ABSTRACT

Type II alveolar cells (AT2s) are critical for basic respiratory homeostasis and tissue repair after lung injury. Prior studies indicate that AT2s also express major histocompatibility complex class II (MHCII) molecules, but how MHCII expression by AT2s is regulated and how it contributes to host defense remain unclear. Here we show that AT2s express high levels of MHCII independent of conventional inflammatory stimuli, and that selective loss of MHCII from AT2s in mice results in modest worsening of respiratory virus disease following influenza and Sendai virus infections. We also find that AT2s exhibit MHCII presentation capacity that is substantially limited compared to professional antigen presenting cells. The combination of constitutive MHCII expression and restrained antigen presentation may position AT2s to contribute to lung adaptive immune responses in a measured fashion, without over-amplifying damaging inflammation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cholera Toxin from Vibrio cholerae, ≥90% (SDS-PAGE), lyophilized powder
Sigma-Aldrich
Y-27632 dihydrochloride, ≥98% (HPLC)
Roche
DNase I, grade II, from bovine pancreas
Sigma-Aldrich
Anti-Prosurfactant Protein C (proSP-C) Antibody, serum, Chemicon®
Sigma-Aldrich
4-Methylumbelliferyl β-D-galactopyranoside, ≥99% (TLC)
Sigma-Aldrich
Tamoxifen, ≥99%